CANCER BIOLOGY & THERAPY is a premier open-access journal published by Taylor & Francis Inc, dedicated to advancing the field of cancer research and treatment. Since its inception in 2002, the journal has evolved to provide a platform for innovative research and groundbreaking findings, addressing critical aspects of cancer biology, pharmacology, and molecular medicine. With an impressive impact factor and recognition as a Q2 journal in vital categories such as Cancer Research, Oncology, and Pharmacology, it holds significant standing in Scopus rankings, reflecting its influence and commitment to disseminating high-quality research. Offering researchers, professionals, and students a wealth of knowledge, CANCER BIOLOGY & THERAPY stands at the forefront of the fight against cancer, presenting the latest developments and therapeutic strategies vital for improving patient outcomes. Accessible to all since 2022, this journal is a must-read for anyone involved in the multifaceted arena of cancer research and treatment.

CANCER INVESTIGATION is a distinguished peer-reviewed journal published by Taylor & Francis Inc, dedicated to the advancing field of cancer research and oncology. With an ISSN of 0735-7907 and E-ISSN of 1532-4192, this journal has been a pivotal resource for professionals and researchers since its inception in 1983, continually contributing to the evolving landscape of cancer investigation until its convergence in 2024. CANCER INVESTIGATION boasts noteworthy rankings in 2023, including Q3 in Cancer Research and Q2 in Medicine (miscellaneous), highlighting its relevance and impact in these critical areas. The journal's commitment to disseminating innovative research and comprehensive reviews makes it an essential platform for those engaged in cancer studies and related disciplines. While currently not available as an open-access publication, CANCER INVESTIGATION remains an invaluable tool for understanding the complexities of cancer, offering insights that drive scientific advancements and improve patient outcomes.

Nature Cancer, published by NATURE PORTFOLIO, stands at the forefront of oncological research with a robust impact within the scientific community. As an esteemed journal with impressive rankings—#12 in Medicine (Oncology) and #8 in Biochemistry, Genetics and Molecular Biology (Cancer Research) according to Scopus, placing it within the 97th and 96th percentiles respectively—Nature Cancer boasts a Q1 category status in both Cancer Research and Oncology for 2023. The journal's commitment to advancing cancer research is crucial, promoting high-quality, peer-reviewed studies that address the complexities of cancer biology and treatment. By facilitating open access to impactful findings, Nature Cancer aims to foster collaboration and inspire innovative approaches among researchers, professionals, and students alike, making significant strides in the global fight against cancer. As this pivotal publication continues its converged years from 2020 to 2024, it heralds a future ripe with transformative insights and breakthroughs in the vital field of oncology.

Blood and Lymphatic Cancer-Targets and Therapy, published by DOVE MEDICAL PRESS LTD, is a vital open-access journal that has been disseminating crucial research and findings in the field of hematology and oncology since 2011. With its ISSN 1179-9889, this journal focuses on the latest therapeutic targets and innovative treatment strategies for blood and lymphatic cancers, contributing significantly to the advancement of knowledge and practice in this specialized area. Designed for researchers, healthcare professionals, and students alike, Blood and Lymphatic Cancer-Targets and Therapy aims to foster a deeper understanding of cancer biology and promote collaborative efforts leading to novel therapeutic interventions. The open-access model ensures that research findings are readily accessible to a global audience, underscoring the journal's commitment to enhancing patient care and fostering educational growth in the cancer domain.

Cancer Research, published by the American Association for Cancer Research, is a premier journal in the field of oncology, renowned for its commitment to advancing cancer research since its inception in 1941. With an impressive impact factor reflecting its vital role in the field, this journal consistently ranks in the Q1 quartile for both Cancer Research and Oncology, positioning it among the top 7.5% of journals in these categories. The journal serves as a crucial platform for researchers, professionals, and students to disseminate and gain insights into groundbreaking studies that shape our understanding of cancer biology, prevention, diagnosis, and treatment. While it is not an open-access publication, its rigorous peer-review process ensures that only high-quality research is published, thus maintaining a standard of excellence in the scientific community. With a strong legacy and an ever-expanding influence, Cancer Research continues to be essential for anyone dedicated to the fight against cancer, showcasing cutting-edge research that drives scientific discovery and innovation.

Trends in Cancer is a leading journal published by CELL PRESS, dedicated to advancing the field of cancer research and oncology. Since its inception in 2015, the journal has rapidly gained a reputation for excellence, securing both Q1 rankings in Cancer Research and Oncology categories for 2023 and boasting impressive Scopus ranks—#13 out of 404 in Medicine Oncology and #9 out of 230 in Biochemistry, Genetics and Molecular Biology, thus placing it in the top 4% of its field. The journal aims to publish high-quality, innovative research that offers new insights into cancer biology and treatment strategies. With a commitment to scholarly rigor and a broad scope that encompasses molecular mechanisms to therapeutic approaches, Trends in Cancer serves as an essential resource for researchers, professionals, and students eager to stay informed about the latest developments in cancer science. Although it is not an open-access journal, its contributions are pivotal in shaping the future of cancer research.

Nature Reviews Clinical Oncology is a premier journal dedicated to the comprehensive exploration and critical evaluation of current advancements in the field of clinical oncology. Published by the esteemed NATURE PORTFOLIO in the United Kingdom, this influential journal boasts an impressive impact factor that reflects its significant role in shaping oncology research. As a Q1 ranked journal in Scopus, it occupies a notable position within the top tier of oncology publications, placing it in the 99th percentile among its peers. With a history of convergence from 2009 to 2024, it presents high-quality content through an open-access model, ensuring accessibility to vital research findings. Researchers, professionals, and students alike will find Nature Reviews Clinical Oncology an invaluable resource for staying abreast of the latest trends, biologic insights, and therapeutic innovations that drive the future of cancer treatment.

Cancer Science, an esteemed journal published by Wiley, stands at the forefront of oncology research, boasting an impressive impact factor and a classification in the Q1 category for its contributions in Cancer Research, Medicine, and Oncology as of 2023. Since its inception in 2003 and transitioning to an Open Access model in 2014, the journal has facilitated global dissemination of critical research findings, ensuring that vital information remains accessible to researchers, clinicians, and students alike. With its comprehensive scope covering cutting-edge discoveries in cancer biochemistry, genetics, and molecular biology, Cancer Science is recognized for its rigorous peer-review process and significant contributions to advancing our understanding of cancer. The journal, located at 111 River St, Hoboken, NJ, is an essential resource for anyone dedicated to improving treatment outcomes and pushing the boundaries of cancer research.

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, published by Elsevier, has established itself as a leading journal in the domains of cancer research, genetics, and oncology, holding a prestigious position in the Q1 quartile rankings in these fields as of 2023. With an ISSN of 0304-419X and an E-ISSN of 1879-2561, this journal aims to disseminate high-quality, impactful reviews that synthesize the latest advancements and findings in cancer biology, treatment modalities, and genomic studies. Its robust indexing and remarkable Scopus rankings—placing it in the 95th to 91st percentiles across various categories—underline its significance for researchers, clinicians, and students passionate about oncology. Operating from its Netherlands headquarters, BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER is dedicated to fostering a comprehensive understanding of the complex biological mechanisms underlying cancer, promoting innovative therapeutic strategies, and guiding future research directions.

SEMINARS IN ONCOLOGY is a premier journal in the field of oncology, published by W B Saunders Co-Elsevier Inc. With its ISSN 0093-7754 and E-ISSN 1532-8708, this esteemed publication has been contributing significantly to cancer research and education since its inception in 1974. The journal currently holds a distinguished position in the academic landscape, ranking in the Q1 category for Hematology and Q2 for Oncology, and featured prominently in Scopus rankings—34th out of 137 in Medicine Hematology, and 108th out of 404 in Medicine Oncology. SEMINARS IN ONCOLOGY aims to disseminate cutting-edge research, critical reviews, and innovative treatment approaches, making it an invaluable resource for researchers, healthcare professionals, and students dedicated to the fight against cancer. Although not an Open Access journal, it maintains a commitment to high-quality, peer-reviewed content, further solidifying its role as a vital reference point in oncological studies. The journal serves as a crucial platform for the exchange of knowledge, insights, and advancements that shape the future of cancer care.